打开网易新闻 查看精彩图片
打开网易新闻 查看精彩图片

参考资料

[1] ClinicalTrials.gov. NCT07764237.

A Study to Investigate Safety, Reactogenicity, and Immunogenicity of mRNA-1365 (Profile 2) in Older Healthy Adults.

[2] ClinicalTrials.gov. NCT05743881.
A Safety, Tolerability, and Immunogenicity Study of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to 24 Months.

[3] Moderna. Review of Investigational RSV (mRNA-1345) and RSV/hMPV (mRNA-1365) Vaccines in Infants and Children <2 Years. FDA VRBPAC, Dec 12, 2024.

[4] FDA. Considerations for Respiratory Syncytial Virus Vaccine Safety in Pediatric Populations. VRBPAC Briefing Document, Dec 12, 2024.

[5] August A, et al. Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults. 2022.

[6] Schnyder Ghamloush S, et al. Safety and Immunogenicity of an mRNA-Based hMPV/PIV3 Combination Vaccine in Seropositive Children. Pediatrics. 2024.

欢迎来到医食参考新媒体矩阵

2023年疫苗接种攻略

阳过了，该怎么打疫苗？最全接种指导手册来了

来源| RNAScript

校稿| Alice编审| Hide / Blue sea

编辑 设计| Leon